• 21 June, 2025

Cipla inks agreement with IICT to develop COVID-19 drug

March 20, 2020 | Friday | News

IICT will be working of existing anti-viral drugs like remdesivir, favipiravir and bolaxavir

Image credit- shuttershock.com

Image credit- shuttershock.com

Mumbai based pharmaceutical company Cipla has teamed up with the Hyderabad based Council of Scientific & Industrial Research-Indian Institute of Chemical Technology (CSIR-IICT) to develop potential candidates for treating COVID-19.

Scientists from IICT will be working of existing anti-viral drugs like remdesivir, favipiravir and bolaxavir.

Further on, Cipla will start the next phase of trials, take up regulatory authority approvals and subsequent mass production of the anti-viral drugs, for the treatment of COVID-19.

 

Comments

× Your session has expired. Please click here to Sign-in or Sign-up
New User? Create Account

Trending Topics

Most Read

Survey Box

Is India’s Integrated DigiTech targeting Affordable Healthcare Access?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy